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Abstract
Background: It has been shown that low concentra-
tions of high-density lipoprotein cholesterol (HDL-C)
are associated with non-alcoholic fatty liver disease
(NAFLD) in patients with type 2 diabetes mellitus
(T2DM). HDL2b, a major subfraction of high-density
lipoprotein (HDL), is more significantly correlatedwith
coronary heart disease (CHD) compared with total
HDL. In this study, we analysed HDL2b in a cohort of
Chinese T2DM subjects with or without NAFLD.
Methods: A highly sensitive and reliable microfluidic
chip method was adopted to measure HDL2b. In total,
48 T2DM patients with NAFLD diagnosed by a B-ultra-
sound were enrolled from our Beijing Community
Pre-Diabetes (BCPD) study cohort. A total of 48 age
and gender matched diabetic controls without NAFLD
were selected from the same population.
Results: Clinical characteristics and serum biochemi-
cal analyses demonstrated a significantly increased
body mass index (BMI), waist circumference, home-
ostasis model assessment-insulin resistant index
(HOMA-IR), total cholesterol (TC), and triglyceride
(TG) concentrations in the NAFLD group. However,
the concentrations of HDL2b and its ratio to total HDL
in NAFLD patients was decreased, compared with
controls (p-0.01). Significantly increased concentra-
tions of high sensitive C-reactive protein (hs-CRP)
(p-0.01) were also found. Multifactor logistic regres-
sion analysis showed that BMI and TG were the pre-
dominant risk factors for fatty liver, while HDL2b was
a protective factor.
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Conclusions: T2DM patients with NAFLD have char-
acteristics including obesity, marked insulin resis-
tance, high TG, high hs-CRP, low HDL2b and a low
HDL2b ratio to total HDL. These factors may increase
the incidence of atherosclerosis as well as the risk of
CHD.
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Introduction
Patients with type 2 diabetes mellitus (T2DM) who
have non-alcoholic fatty liver disease (NAFLD) often
have an atherogenic lipoprotein profile of high tri-
glycerides (TG), and lower high-density lipoprotein
cholesterol (HDL-C) (1). T2DM is associated with a
marked increase in morbidity and mortality from cor-
onary heart disease (CHD) (2). HDL-C is an important
factor associated with an increased risk of future
ischaemic heart disease (3). There is a significant
inverse correlation between the large and low-density
subfractions of HDL (HDL2a, HDL2b and HDL3a) and
CHD, and a significant positive correlation between
the small but high-density subfraction of HDL (HDL3b
and HDL3c) and CHD (4, 5). Moreover, it has been
shown that HDL2b is a more significant factor
correlated with CHD compared with total HDL (6, 7).
Among these alterations in dyslipidaemia, changes in
HDL subfractions have not been thoroughly investi-
gated due to limitations in the quantitative methods
used to measure HDL subfractions. These methods
include sequential or gradient ultracentrifugation,
gradient gel electrophoresis (8, 9), ion mobility meas-
urements, capillary isotachophoresis (10) and high
performance liquid chromatography (HPLC) (11).
Some of these methods are labour intensive, expen-
sive and time consuming. Others require expert tech-
nical personnel for proper performance. Although
lipoprotein subfractions can be detected by nuclear
magnetic resonance (NMR), this technology has only
been developed in recent years and has not been
widely applied due to complex calculations and
instrument requirements (12). We analysed HDL2b
and other cardiovascular risk factors in Chinese T2DM
patients with and without NAFLD using a novel micro-
fluidic chip-based technique. This technique is fast,
highly reproducible, easy to operate and has been
successfully used to measure HDL2b in subjects from
the Prospective Cardiovascular Munster (PROCAM)
study (7). Our study revealed the characteristics and
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Figure 1 Electrophoretic trace of microfluidic separation.
(A) Agilent 2100 bioanalyzer Agilent and the high sensitivity
protein assay chip. (B) Lipid profile of a patient with fatty
liver. (C) Lipid profile of a control patient. The electrophoretic
trace consists of the lower marker (LM), high-density lipo-
protein (HDL) region and upper marker (UM). Both markers
are part of the sample dilution buffer and are used for sam-
ple alignment. A deconvolution algorithm identifies five indi-
vidual peaks in the HDL region. Peak 1 represents the HDL3
component; peak 2 represents HDL3 and HDL2a; peak 3 is
HDL2b; peak 4 has somehow fallen to the density range of
HDL3; peak 5 is a systematic peak – a baseline of the system
across all subfractions.




The study subjects were selected from an ongoing large-
scale population-based cohort research study, the Beijing
Community Pre-Diabetes (BCPD) study. The BCPD study was
designed to facilitate the conduct of genetic epidemiology
investigations and clinical trials. It was conducted in the
community of Nanfaxin, a rural suburb of Beijing. With the
approval of the medical Ethical Committee of Beijing Ton-
gren Hospital, Capital Medical University, the BCPD study
was begun in May 2007. We mailed screening requests to all
inhabitants aged from 35 to 74 years (ns9033). We received
responses from 3457 and obtained written informed con-
sent. Of the 3457 responders, 3294 individuals finished dia-
betes screening, 1063 were male (32.3%) and 2231 female
(67.7%). A total of 499 T2DM subjects were identified, of
whom 285 subjects had previously been diagnosed. The oth-
er 214 T2DM subjects were identified using the oral glucose
tolerance test.
Study subjects
Of the 499 subjects with T2DM, 131 subjects were identified
as having fatty liver. Based on the criteria of inclusion and
exclusion, 48 T2DM subjects with NAFLD were randomly
selected, and 48 gender and age matched T2DM subjects
without NAFLD were chosen for the control group. Criteria
for participation included confirmed diagnosis of type 2 dia-
betes in accordance with the 1999 World Health Organization
(WHO) diagnostic criteria (13), duration -5 years, and a con-
firmed diagnosis of fatty liver in accordance with guidelines
for the assessment and management of NAFLD in the Asia-
Pacific region (14). Fatty liver can be diagnosed by the pres-
ence of at least 2 of 3 abnormal findings on abdominal
ultrasonography: w1x diffusely increased echogenicity
(‘‘bright liver’’), with liver echogenicity greater than the kid-
ney w2x blurring of hepatic vessels w3x deep attenuation of the
ultrasound signal.
Patients were excluded if they had a known history of CHD
or hepatic disease, serum TG )4.52 mmol/L (400 mg/dL),
treatment with insulin, statins or fibrates, treatment with
sulphonylureas, repaglinide, or metformin at submaximal
doses (alone or in combination) within the past 6 months,
substance abuse, or those whose weekly consumption of
more than 40 g of alcohol.
Physical examinations (measurements of waist circumfer-
ence, height, weight and blood pressure) were performed by
a trained nurse. Body mass index (BMI) was calculated as
weight in kilograms divided by the square of the height in
meters. Fasting sera and EDTA anticoagulant blood samples
were obtained and stored at –808C prior to biochemical anal-
ysis. Fasting blood glucose (FBG), total cholesterol (TC), TG,
low-density lipoprotein cholesterol (LDL-C), alanine amino-
transferase (ALT), creatinine, high sensitive C-reactive pro-
tein (hs-CRP), total bilirubin (TBIL), and direct bilirubin (DBIL)
were measured at the Beijing Tongren Hospital Laboratory
using the Beckman Coulter Unicel DX800 (Beckman Coulter
Inc, Fullerton, CA, USA). Plasma insulin was measured with
an ELISA kit from Linco (Linco Research, St. Charles, MO,
USA). Haemoglobin A1c (HbA1c) was measured using HPLC
with the Bio Rad Variant (Bio Rad Laboratories Inc, Califor-
nia, USA).
LipoChip analysis
The concentrations of total HDL and HDL2b were measured
using two quality control (QC) materials at 0.62 mmol/L and
1.50 mmol/L of HDL-C obtained from Solomon Park Research
Institute (Kirkland, WA, USA). All tests were performed using
the Agilent 2100 Bioanalyser (Agilent, Waldbronn, Germany)
with a newly developed HDL subfraction assay (Figure 1A).
In brief, a linear polymer solution of poly N,N-dimethyl acryl-
amide (PDMA; Polysciences, Warrington, PA, USA) is used
as the separation matrix. Serum samples, calibrator and QC
materials (Solomon Park Research Institute, Kirkland, WA,
USA) were diluted 1:50 in the sample buffer (250 mM TAPS,
pH 7.5) in the presence of a lipophilic fluorescent dye (DY-
676, Dyomics, Jena, Germany). These were then incubated
for 15 min prior to analysis. Buffer wells of the microfluidic
chips (Caliper Life Sciences, Hopkinton, MA, USA) were filled
with 10 mL of the polymer. The diluted calibrators and QC
materials were placed into the appropriate wells on the
microfluidic chips, and the patient samples were added to
the remaining nine wells. Separation was performed by
starting the chip which executed a software script that
applied current and voltage in a predefined manner. Fluo-
rescent stained lipoproteins were detected with laser-
induced fluorescence at 680 nm. Upon completion of the
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run, the chip was discarded and the electrodes cleaned with
a designated cleaning chip. The entire procedure was per-
formed in -1 h.
Statistical analysis
Normal distributed data were expressed as means"stan-
dard deviations (SDs). Non-normal distributed values were
expressed as medians and quartile ranges wM(QR)x. Non-nor-
mal distributed values were logarithmically transformed for
parametric statistical analysis. Significant differences in
parameters between patients with fatty liver and controls
were assessed with Student’s t-test. The risk of developing
fatty liver was analysed by single factor logistic regression.
Multivariate analysis was then performed by binary logistic
regression using forward stepwise and Wald statistical cri-
teria. The statistical analysis was calculated in SPSS 11.5
(SPSS Inc, Chicago, IL, USA). Statistical significance was
defined as p-0.05, and all hypotheses were tested using
two-sided analysis.
Results
Figure 1A shows the Agilent 2100 Bioanalyser and the
high sensitivity HDL subfraction assay chip. Figure 1B,
C shows two groups representating the electropho-
togram of serum total HDL separated by the size-to-
charge ratio with microfluidics gel electrophoresis.
The electrophoretic trace shows the lower marker
(LM), HDL region and upper marker (UM), as shown
in Figure 1B. Both markers are part of the sample dilu-
tion buffer and are used for sample alignment. A
deconvolution algorithm identified five individual
peaks in the HDL region. Peak 1 represents the HDL3
component; peak 2 represents HDL3 and HDL2a; peak
3 is HDL2b; peak 4 has unexpectedly fallen into the
density range of HDL3; peak 5 is a systematic peak
representing a baseline of the system across all sub-
fractions. It shows that all components of HDL are
decreased in patients with T2DM and NAFLD (Figure
1B, C).
Table 1 and Figure 2 show the comparisons of
patient demographics and blood testing results
between patients with fatty liver and controls.
Comparison of patient demographics demonstrated
no statistical differences in age, sex, body height and
blood pressure, but significantly increased BMI, waist
circumference, hip circumference and waist-to-hip
ratio (WHR) (p-0.05) in patients with T2DM and
NAFLD compared with the control group.
Comparison of blood test data showed no statistical
differences in FBG, HbA1c, TBIL, DBIL, LDL-C, TC and
creatinine, but showed significantly increased con-
centrations of fasting insulin, homeostasis model
assessment-insulin resistant index (HOMA-IR), ALT,
TG and hs-CRP (p-0.01). There were also decreased
concentrations of HDL-C, HDL2b (p-0.01) and
decreased HDL2b to total HDL (p-0.01) in T2DM
patients with NAFLD when compared with the control
group.
Table 2 shows the logistic regression analysis of the
fatty liver group and the control group. Logistic
regression analyses demonstrated that BMI, waist cir-
cumference, hip circumference, WHR, fasting insulin,
HOMA-IR, ALT, TG and hs-CRP were independent risk
factors which may affect T2DM patients with NAFLD.
However, HDL-C, HDL2b and the HDL2b ratio to total
HDL were protective factors.
Table 3 shows the multifactor logistic regression
analysis of fatty liver patients and the control group.
It shows that BMI and TG were the predominant risk
factors, while HDL2b is a protective factor against fat-
ty liver.
Discussion
NAFLD is a condition that is becoming increasingly
common, and in some cases can progress to end-
stage liver disease (15). The prevalence of NAFLD in
the general population ranges from 13% to 15% (16),
while the prevalence of NAFLD in subjects with T2DM
has been reported to range from 21% to 55% (17). The
results of this study show that T2DM patients with
NAFLD are more likely to have obesity, insulin resis-
tance and disorders of lipid metabolism.
HDL-C plays a key role in reverse cholesterol trans-
portation. Its functions include antiatherogenic, anti-
oxidant, anti-inflammatory, anti-apoptosis and
anti-thrombotic effects (18). HDL is comprised of a
heterogeneous group of lipoproteins that may be
classified by decreasing size as HDL2b, HDL2a,
HDL3a, HDL3b, HDL3c (19). These HDL subclasses
have different antiatherogenic characteristics, such as
their different capacity to promote cholesterol efflux
from peripheral tissues (20). HDL2b plays a significant
role of protection against atherosclerosis and coro-
nary artery disease (21). In humans, HDL subclasses
may be influenced by several factors including eth-
nicity (22), TG concentrations (23), antidiabetic or lipid
regulating drugs (24, 25), blood glucose (26, 27) and
CHD (5, 7). In this matched case-control study using
a representative sample population with strict inclu-
sion criteria to exclude the impact of factors such as
FBG and HbA1c, we found significantly decreased
HDL2b (p-0.01) and a decreased HDL2b to total HDL
ratio (p-0.01) in T2DM patients with NAFLD as com-
pared with the control group. This difference may
result in an increased risk of atherosclerosis and CHD
in patients with T2DM and NAFLD. The logistic regres-
sion analyses demonstrated that BMI, waist circum-
ference, hip circumference, WHR, fasting insulin,
HOMA-IR, ALT, TG and hs-CRP were independent risk
factors for NAFLD, while HDL-C, HDL2b and the ratio
of HDL2b to total HDL were protective factors. Multi-
factorial logistic regression analysis showed that BMI
and TG are the predominant risk factors, and HDL2b
is a protective factor against fatty liver.
C-reactive protein (CRP) is one of the major acute
phase proteins and is a marker of systemic inflam-
mation. In contrast to standard CRP assays, the hs-
CRP assay allows for measurement of low CRP
concentrations seen with even low-grade inflamma-
tion. Recently, increased serum hs-CRP was reported
to be a strong predictor for future cardiovascular
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Table 1 Comparisons of patient demographics and results of blood test analysis in patients with fatty liver and controls.
Characteristics Fatty liver patients Controls
Subjects, n 48 48
Female, % 52.08 52.08
Age, years 54.90"8.66 54.92"9.19
Body height, cm 162.15"8.51 160.94"7.68
Body weight, kg 76.81"10.32b 67.82"12.10
BMI, kg/m2 29.19"3.03b 26.07"3.43
Waist circumference, cm 96.20"7.59b 88.93"10.90
Hip circumference, cm 104.14"6.47b 98.67"7.08
WHR, % 92.35"4.98a 89.92"6.48
Systolic blood pressure, mm Hg 138.85"17.83 139.60"19.72
Diastolic blood pressure, mm Hg 83.50 (12.50) 85.00 (13.00)
TBIL, mmol/L 12.59"3.92 13.30"6.92
DBIL, mmol/L 2.85"0.84 2.91"1.44
HbA1c, % 8.26"1.29 8.03"1.91
Fasting glucose, mmol/L 7.41 (1.89) 6.69 (2.56)
Fasting insulin, pmol/L 7.61 (7.51)b 3.66 (4.96)
HOMA-IR 2.60 (2.28)b 1.20 (1.57)
hs-CRP, mg/L 4.27"3.16b 2.41"1.84
ALT, IU/L 29.0 (15.5)b 23.00 (8.50)
Serum creatinine, mmol/L 58.00 (23.25) 52.50 (28.75)
LDL-C, mmol/L 3.37"0.99 3.28"0.69
TC, mmol/L 4.93"0.90 4.97"0.81
TG, mmol/L 2.39"0.96b 1.55"0.75
HDL-C, mmol/L 1.04"0.22b 1.27"0.26
HDL2b, mmol/L 0.21"0.07b 0.28"0.11
HDL2b ratio, % 20.35"3.91b 23.43"5.32
Means"SD, n (%), M(QR), ap-0.05, bp-0.01 compare with controls.
Figure 2 Comparison of HDL2b, HDL2b ratio (%), high sensitive C-reactive protein (hs-CRP) and homesostasis model assess-
ment-insulin resistant index (HOMA-IR) between patients with fatty liver and controls.
events. The increased hs-CRP degree is related to the
severity of CHD in CHD patients undergoing coronary
angiography (28). Multiple prospective studies have
demonstrated that hs-CRP is an independent and
good predictor of future cardiovascular events (29,
30). Inflammatory processes play a pivotal role in the
pathogenesis of atherosclerosis and mediate many of
the stages of atheroma development from initial leu-
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Table 2 Logistic regression analyses of fatty liver patients and controls.
Regression Exp (b) Exp (B) p-Value 95% CI for Exp (B)
BMI 0.30"0.08 1.35 0.000 1.16;1.56
Waist circumference, cm 0.08"0.03 1.09 0.001 1.04;1.14
Hip circumference, cm 0.12"0.03 1.13 0.000 1.05;1.20
WHR, % 0.07"0.04 1.08 0.046 1.00;1.16
Fasting insulin, pmol/L 0.23"0.06 1.25 0.000 1.11;1.42
HOMA-IR 0.56"0.18 1.76 0.002 1.24;2.49
hs-CRP, mg/L 0.30"0.10 1.35 0.002 1.12;1.62
ALT, IU/L 0.04"0.15 1.04 0.021 1.01;1.07
TG, mmol/L 1.18"0.30 3.26 0.000 1.80;5.91
HDL-C, mmol/L –0.12"0.03 0.89 0.000 0.84;0.94
HDL2b, mmol/L –0.34"0.08 0.71 0.000 0.61;0.84
HDL2b ratio, % –0.15"0.05 0.86 0.004 0.78;0.95
Table 3 The multifactor logistic regression analyses of fatty liver patients and controls.
Regression Exp (b) Exp (B) p-Value 95% CI for Exp (B)
BMI 0.31"0.09 1.37 0.001 1.15;1.63
TG, mmol/L 1.03"0.38 2.79 0.007 1.33;5.85
HDL2b, mmol/L –0.24"0.10 0.79 0.016 0.65;0.96
The multivariate logistic regression with the independent variable (HOMA-IR, ALT, TG, hs-CRP, HDL2b, BMI, waist circumfer-
ence and hip circumference) and the dependent variable (fatty liver) were carried out. The probability to enter the model was
set at 0.05 and the probability to remove from the model was set at 0.10.
kocyte recruitment to eventual rupture of an unstable
atherosclerotic plaque. Pathogen infection may be an
important cause of CHD. A variety of inflammatory
markers such as interleukin-6 (IL-6), and tumour
necrosis factors (TNF) are closely related to the devel-
opment of CHD (31). hs-CRP has been regarded as the
most powerful marker of inflammation for predicting
future cardiovascular disease (32). In this study, hs-
CRP concentrations (p-0.01) in patients with T2DM
and NAFLD were significantly increased compared
with the control group.
In conclusion, we found that patients with T2DM
and NAFLD had characteristics including obesity,
hyperinsulinaemia, marked insulin resistance, high
TG, high hs-CRP, low HDL2b and a low HDL2b to total
HDL ration. These factors may increase the incidence
of atherosclerosis as well as the risk of CHD.
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